Abstract
The primary goal of phase I studies in oncology is to determine the MTD (Maximum Tolerated Dose) for a drug. This MTD is determined with respect to an accepted risk (usually 33%) to see a limiting toxity for patients. In this paper we propose a new mathematical model to determine the MTD. An important feature of this model is that the limiting toxicity can be formulated as a combination of several basic graded toxicities such as hematologic or neurological. Another feature is the possibility to take into account several patient covariates to individualize the determination of the MTD. The model is a bayesian model where some prior information has been considered. The model is expected to work better than traditional empirical schemes for determining the MTD because it uses at every step all the available information on patients, and adds some major improvements as compared with existing CRM strategies because it uses whole data made available, including low-grades toxicities. Finally the model has been validated with a retrospective data set on 17 patients from a phase I study on paclitaxel in pediatric oncology. Calculated MTDs for each patient were found to be markedly different than the doses actually given following a traditionnal dose-escalation methodology. Results suggest that our new model provides a better and safer way to drive dose-escalation in phase-I trials as compared with traditionnal schemes.
Keywords: MTD, DLT, CRM, Toxicity grades, Skewed Logistic, MCMC methods, Prior distributions
Current Topics in Medicinal Chemistry
Title:A New Model for Determining the MTD During Phase-I Trials in Pediatric Oncology
Volume: 12 Issue: 15
Author(s): C. Faivre, D. Barbolosi and A. Iliadis
Affiliation:
Keywords: MTD, DLT, CRM, Toxicity grades, Skewed Logistic, MCMC methods, Prior distributions
Abstract: The primary goal of phase I studies in oncology is to determine the MTD (Maximum Tolerated Dose) for a drug. This MTD is determined with respect to an accepted risk (usually 33%) to see a limiting toxity for patients. In this paper we propose a new mathematical model to determine the MTD. An important feature of this model is that the limiting toxicity can be formulated as a combination of several basic graded toxicities such as hematologic or neurological. Another feature is the possibility to take into account several patient covariates to individualize the determination of the MTD. The model is a bayesian model where some prior information has been considered. The model is expected to work better than traditional empirical schemes for determining the MTD because it uses at every step all the available information on patients, and adds some major improvements as compared with existing CRM strategies because it uses whole data made available, including low-grades toxicities. Finally the model has been validated with a retrospective data set on 17 patients from a phase I study on paclitaxel in pediatric oncology. Calculated MTDs for each patient were found to be markedly different than the doses actually given following a traditionnal dose-escalation methodology. Results suggest that our new model provides a better and safer way to drive dose-escalation in phase-I trials as compared with traditionnal schemes.
Export Options
About this article
Cite this article as:
Faivre C., Barbolosi D. and Iliadis A., A New Model for Determining the MTD During Phase-I Trials in Pediatric Oncology, Current Topics in Medicinal Chemistry 2012; 12 (15) . https://dx.doi.org/10.2174/156802612803531469
DOI https://dx.doi.org/10.2174/156802612803531469 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Science Ph.D. and Science Postdoctoral Advisors for the 21st Century: A Path To Successful Technology Transfer
Technology Transfer and Entrepreneurship (Discontinued) Thalidomide as an Immunotherapeutic Agent: The Effects on Neutrophil- Mediated Inflammation
Current Pharmaceutical Design Liver Stem Cells: From Preface to Advancements
Current Stem Cell Research & Therapy Mycotoxins Levels in Human Milk: A Menace to Infants and Children Health
Current Nutrition & Food Science Eggshell Membrane Based Turmeric Extract Loaded Orally Disintegrating Films
Current Drug Delivery Targeting the Epidermal Growth Factor Receptor in Glioblastoma Treatment
Current Signal Transduction Therapy Glucagon and Glucagon-Like Peptide Receptors as Drug Targets
Current Pharmaceutical Design An Insight into Molecular Mechanisms and Novel Therapeutic Approaches in Epileptogenesis
CNS & Neurological Disorders - Drug Targets Novel Adjuvants for Vaccines
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Resistance to Peloruside A and Laulimalide: Functional Significance of Acquired βI-tubulin Mutations at Sites Important for Drug-Tubulin Binding
Current Cancer Drug Targets Gene Therapy for Gastric Diseases
Current Gene Therapy Cancer Vaccines: Emphasis on Pediatric Cancers
Current Pharmaceutical Design Review on Patents for Ubiquitin-Proteasome Inhibitor as Medical Advance in Major Human Diseases
Recent Patents on Biomedical Engineering (Discontinued) Adult Stem Cell Therapy for Acute Brain Injury in Children
CNS & Neurological Disorders - Drug Targets Diabetes and Vascular Disease: Basic Concepts of Nitric Oxide Physiology, Endothelial Dysfunction, Oxidative Stress and Therapeutic Possibilities
Current Vascular Pharmacology Role of mTOR in Hematological Malignancies
Current Cancer Therapy Reviews Immunobiology of Herpes Simplex Virus and Cytomegalovirus Infections of the Fetus and Newborn
Current Immunology Reviews (Discontinued) Cancer Stem Cells and the Tumor Microenvironment: Soloists or Choral Singers
Current Pharmaceutical Biotechnology Nitric Oxide and Arginine Dysregulation: A Novel Pathway to Pulmonary Hypertension in Hemolytic Disorders
Current Molecular Medicine NO to Breast: When, Why and Why Not?
Current Pharmaceutical Design